0001661059 false 0001661059 2021-11-04 2021-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 4, 2021


NextCure, Inc.

(Exact name of registrant as specified in charter)


Delaware   001-38905   47-5231247

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


9000 Virginia Manor Road, Suite 200

Beltsville, Maryland

(Address of principal executive offices)   (Zip Code)


(240) 399-4900




Registrant’s telephone number, including area code




(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share NXTC Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02Results of Operations and Financial Condition


On November 4, 2021, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.


The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01Financial Statements and Exhibits


(d) Exhibits.




99.1   Press release issued by NextCure, Inc. dated November 4, 2021.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 4, 2021  
  /s/ Steven P. Cobourn
  Steven P. Cobourn
  Chief Financial Officer






Exhibit 99.1


A picture containing clipart

Description automatically generated


NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update


BELTSVILLE, Md. – November 4, 2021NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2021 financial results and provided a business update.


“We are pleased to present clinical and biomarker data for our NC318 and NC410 programs at the upcoming SITC annual meeting,” said Michael Richman, NextCure’s president and chief executive officer. “In addition, we will host a virtual research and development update event following the conference on November 15th. The event will also feature Dr. Roy Herbst who will highlight the significant remaining unmet need in the treatment of lung cancer. Dr Herbst is currently a collaborator in the Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with advanced non-small cell lung cancer.”


Business Highlights and Upcoming Milestones


·Published preclinical data pertaining to the NC410 program in the open access journal, Frontiers in Immunology.

·Appointed Ellen G. Feigal, M.D., a Partner and Head of the Biologics Practice at NDA Partners LLC, and Anne Borgman, M.D., former Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, to the Board of Directors.

·Appointed Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board.

·Clinical and biomarker data for NC318 and NC410 programs to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting on November 10-14, 2021.

·Hosting a virtual research and development update event on November 15, 2021, at 4:30 pm EST.

·Announced presentations by collaborators at the American Society of Hematology Annual Meeting (ASH) on December 11-14, 2021, two research studies evaluating the role of Siglec-15 as a therapeutic target in childhood leukemia and the impact of a LAIR-1 antibody that selectively targets AML stem cells.


Financial Guidance


Based on its current research and development plans, NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.


Financial Results for Quarter Ended September 30, 2021


·Cash, cash equivalents and marketable securities as of September 30, 2021, were $235.3 million, as compared to $283.4 million as of December 31, 2020. The decrease of $48.1 million primarily reflects cash used to fund operations, to purchase fixed assets, and to repay a term loan.

·Research and development expenses were $13.6 million for the quarter ended September 30, 2021, as compared to $12.7 million for the quarter ended September 30, 2020. The increase was driven primarily by clinical-related costs, partially offset by timing of research and manufacturing supply costs.





·General and administrative expenses were $4.9 million for the quarter ended September 30, 2020, as compared to $4.7 million for the quarter ended September 30, 2020. The increase was primarily related to personnel-related costs.

·Net loss was $17.9 million for the quarter ended September 30, 2021, as compared to $16.4 million for the quarter ended September 30, 2020. The increase in net loss for the quarter was primarily due to increased research and development expenses and increased general and administrative expenses from an increase in headcount.


About NextCure, Inc.


NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com


Forward-Looking Statements


This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,” “will,” “potential,” “expects,” “believes,” “intends,” “hope,” “towards,” “forward,” “later” and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for NC410 and expected upcoming milestones, the potential benefits of NC410, and NextCure’s plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure’s business, including NextCure’s clinical trials, third parties on which NextCure relies and NextCure’s operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and no products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure’s FIND-IO™ platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including in Item 1A of NextCure’s most recent Form 10-K and elsewhere in the Company’s filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.







(unaudited, in thousands, except share and per share amounts)


   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
Revenue from former research and development arrangement  $   $   $   $22,378 
Operating expenses:                    
Research and development   13,597    12,740    37,928    34,448 
General and administrative   4,911    4,659    15,766    12,918 
Total operating expenses   18,508    17,399    53,694    47,366 
Loss from operations   (18,508)   (17,399)   (53,694)   (24,988)
Other income, net   578    1,032    1,244    3,846 
Net loss  $(17,930)  $(16,367)  $(52,450)  $(21,142)
Loss per share - basic and diluted  $(0.65)  $(0.59)  $(1.90)  $(0.77)
Weighted-average shares outstanding - basic and diluted   27,615,038    27,547,737    27,607,685    27,524,350 
Comprehensive loss:                    
Net loss  $(17,930)  $(16,367)  $(52,450)  $(21,142)
Unrealized gain (loss) on marketable securities   66    (637)   (908)   1,298 
Total comprehensive loss  $(17,864)  $(17,004)  $(53,358)  $(19,844)







(unaudited, in thousands, except share and per share amounts)


   September 30,   December 31, 
   2021   2020 
Current assets:          
Cash and cash equivalents  $36,664   $32,772 
Marketable securities   198,672    250,676 
Restricted cash   39    1,706 
Prepaid expenses and other current assets   7,661    2,824 
Total current assets   243,036    287,978 
Property and equipment, net   14,208    15,809 
Other assets   581    2,857 
Total assets  $257,825   $306,644 
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $2,946   $3,901 
Accrued liabilities   4,232    4,627 
Deferred rent, current portion   198    130 
Term loan, current portion       1,667 
Total current liabilities   7,376    10,325 
Deferred rent, net of current portion   2,223    792 
Term loan, net of current portion       1,806 
Total liabilities   9,599    12,923 
Stockholders’ equity:          
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020        
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at September 30, 2021 and December 31, 2020; 27,619,763 and 27,568,802 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively   28    28 
Additional paid-in capital   418,414    410,551 
Accumulated other comprehensive (loss) income   (129)   779 
Accumulated deficit   (170,087)   (117,637)
Total stockholders’ equity   248,226    293,721 
Total liabilities and stockholders’ equity  $257,825   $306,644 





Investor Inquiries


Timothy Mayer, Ph.D.

NextCure, Inc.

Chief Operating Officer

(240) 762-6486